Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01980342 · ClinicalTrials.gov registry record · Phase 4

Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz

A Phase 4 study, sponsored by Johns Hopkins University.

Terminated
Registry status
Phase 4
Development phase
1
Enrollment target

NCT01980342: Clinical Trial Phase 4 study, sponsored by Johns Hopkins University.

NCT01980342 is a Phase 4 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01980342, a Phase 4 study, was terminated before completion, sponsored by Johns Hopkins University.

TERMINATED
Registry status
Phase 4
Development phase
1 participants
Enrollment target

Study Summary

This study evaluates whether there is an interaction between etonogestrel, the progestin hormone released by the contraceptive implant Nexplanon, and efavirenz, a common medication used to treat HIV. The endpoints measured in this study will help determine if such an interaction leads to decreased contraceptive efficacy of the contraceptive implant.

Interventions

  • DRUG Efavirenz

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2014-10
Est. Completion 2018-04-04
Phase Phase 4

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT01980342

The ClinicalTrials.gov registry entry for NCT01980342 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Efavirenz is the first listed.

NCT01980342 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01980342 about?

NCT01980342 is a clinical study titled "Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz". This study evaluates whether there is an interaction between etonogestrel, the progestin hormone released by the contraceptive implant Nexplanon, and efavirenz, a common medication used to treat HIV. The endpoints measured in this study will help determine if such an interaction leads to decreased c...

What is the current status of trial NCT01980342?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2014-10. Estimated completion is 2018-04-04.

What interventions are being tested in trial NCT01980342?

The interventions under investigation include: Efavirenz (DRUG).

Who is sponsoring clinical trial NCT01980342?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.